While early models suggested that XPO1 inhibitors act primarily by restoring nuclear localization of tumor suppressors, experimental evidence shows that these agents exert antitumor activity even in cells lacking functional p53, RB, or p21, indicating a broader mechanism beyond tumor suppressor retention [26,35]. This evidence concerns the gene XPO1 and neoplasm.